FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2998896835> ?p ?o ?g. }

• W2998896835 endingPage "e0227600" @default.
• W2998896835 startingPage "e0227600" @default.
• W2998896835 abstract "Background Poor adherence to antiretroviral drugs and viral resistance are the main drivers of treatment failure in HIV-infected patients. In sub-Saharan Africa, avoidance of treatment failure on second-line protease inhibitor therapy is critical as treatment options are limited. Methods In the prospective observational study of the Kilombero & Ulanga Antiretroviral Cohort in rural Tanzania, we assessed virologic failure (viral load ≥1,000 copies/mL) and drug resistance mutations in bio-banked plasma samples 6–12 months after initiation of a protease inhibitor-based treatment regimen. Additionally, viral load was measured before start of protease inhibitor, a second time between 1–5 years after start, and at suspected treatment failure in patients with available bio-banked samples. We performed resistance testing if viral load was ≥1000 copies/ml. Risk factors for virologic failure were analyzed using logistic regression. Results In total, 252 patients were included; of those 56% were female and 21% children. Virologic failure occurred 6–12 months after the start of a protease inhibitor in 26/199 (13.1%) of adults and 7/53 of children (13.2%). The prevalence of virologic failure did not change over time. Nucleoside reverse transcriptase inhibitors drug resistance mutation testing performed at 6–12 months showed a positive signal in only 9/16 adults. No cases of resistance mutations for protease inhibitors were seen at this time. In samples taken between 1–5 years protease inhibitor resistance was demonstrated in 2/7 adults. In adult samples before protease inhibitor start, resistance to nucleoside reverse transcriptase inhibitors was detected in 30/41, and to non-nucleoside reverse-transcriptase inhibitors in 35/41 patients. In 15/16 pediatric samples, resistance to both drug classes but not for protease inhibitors was present. Conclusion Our study confirms high early failure rates in adults and children treated with protease inhibitors, even in the absence of protease inhibitors resistance mutations, suggesting an urgent need for adherence support in this setting." @default.
• W2998896835 created "2020-01-23" @default.
• W2998896835 creator A5003912411 @default.
• W2998896835 creator A5024314365 @default.
• W2998896835 creator A5033053998 @default.
• W2998896835 creator A5048271430 @default.
• W2998896835 creator A5052780767 @default.
• W2998896835 creator A5052791763 @default.
• W2998896835 creator A5070365161 @default.
• W2998896835 creator A5078441202 @default.
• W2998896835 creator A5087140749 @default.
• W2998896835 creator A5089532923 @default.
• W2998896835 date "2020-01-13" @default.
• W2998896835 modified "2023-10-16" @default.
• W2998896835 title "High failure rates of protease inhibitor-based antiretroviral treatment in rural Tanzania – A prospective cohort study" @default.
• W2998896835 cites W1966390940 @default.
• W2998896835 cites W1967241050 @default.
• W2998896835 cites W1989878476 @default.
• W2998896835 cites W2011461790 @default.
• W2998896835 cites W2039838339 @default.
• W2998896835 cites W2082808145 @default.
• W2998896835 cites W2110784731 @default.
• W2998896835 cites W2125756020 @default.
• W2998896835 cites W2129186628 @default.
• W2998896835 cites W2130068726 @default.
• W2998896835 cites W2339835327 @default.
• W2998896835 cites W2434557170 @default.
• W2998896835 cites W2461327773 @default.
• W2998896835 cites W2469642414 @default.
• W2998896835 cites W2472059781 @default.
• W2998896835 cites W2526215611 @default.
• W2998896835 cites W2604804796 @default.
• W2998896835 cites W2610466423 @default.
• W2998896835 cites W2622833699 @default.
• W2998896835 cites W2641925300 @default.
• W2998896835 cites W2731882942 @default.
• W2998896835 cites W2736458542 @default.
• W2998896835 cites W2737863948 @default.
• W2998896835 cites W2766916692 @default.
• W2998896835 cites W2768535842 @default.
• W2998896835 cites W2785066616 @default.
• W2998896835 doi "https://doi.org/10.1371/journal.pone.0227600" @default.
• W2998896835 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6957142" @default.
• W2998896835 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31929566" @default.
• W2998896835 hasPublicationYear "2020" @default.
• W2998896835 type Work @default.
• W2998896835 sameAs 2998896835 @default.
• W2998896835 citedByCount "7" @default.
• W2998896835 countsByYear W29988968352021 @default.
• W2998896835 countsByYear W29988968352022 @default.
• W2998896835 countsByYear W29988968352023 @default.
• W2998896835 crossrefType "journal-article" @default.
• W2998896835 hasAuthorship W2998896835A5003912411 @default.
• W2998896835 hasAuthorship W2998896835A5024314365 @default.
• W2998896835 hasAuthorship W2998896835A5033053998 @default.
• W2998896835 hasAuthorship W2998896835A5048271430 @default.
• W2998896835 hasAuthorship W2998896835A5052780767 @default.
• W2998896835 hasAuthorship W2998896835A5052791763 @default.
• W2998896835 hasAuthorship W2998896835A5070365161 @default.
• W2998896835 hasAuthorship W2998896835A5078441202 @default.
• W2998896835 hasAuthorship W2998896835A5087140749 @default.
• W2998896835 hasAuthorship W2998896835A5089532923 @default.
• W2998896835 hasBestOaLocation W29988968351 @default.
• W2998896835 hasConcept C114851261 @default.
• W2998896835 hasConcept C126322002 @default.
• W2998896835 hasConcept C142462285 @default.
• W2998896835 hasConcept C159047783 @default.
• W2998896835 hasConcept C181199279 @default.
• W2998896835 hasConcept C188816634 @default.
• W2998896835 hasConcept C201903717 @default.
• W2998896835 hasConcept C2776714187 @default.
• W2998896835 hasConcept C2778451633 @default.
• W2998896835 hasConcept C2781143361 @default.
• W2998896835 hasConcept C2781413609 @default.
• W2998896835 hasConcept C2993143319 @default.
• W2998896835 hasConcept C3013748606 @default.
• W2998896835 hasConcept C55493867 @default.
• W2998896835 hasConcept C71924100 @default.
• W2998896835 hasConcept C86803240 @default.
• W2998896835 hasConcept C89423630 @default.
• W2998896835 hasConceptScore W2998896835C114851261 @default.
• W2998896835 hasConceptScore W2998896835C126322002 @default.
• W2998896835 hasConceptScore W2998896835C142462285 @default.
• W2998896835 hasConceptScore W2998896835C159047783 @default.
• W2998896835 hasConceptScore W2998896835C181199279 @default.
• W2998896835 hasConceptScore W2998896835C188816634 @default.
• W2998896835 hasConceptScore W2998896835C201903717 @default.
• W2998896835 hasConceptScore W2998896835C2776714187 @default.
• W2998896835 hasConceptScore W2998896835C2778451633 @default.
• W2998896835 hasConceptScore W2998896835C2781143361 @default.
• W2998896835 hasConceptScore W2998896835C2781413609 @default.
• W2998896835 hasConceptScore W2998896835C2993143319 @default.
• W2998896835 hasConceptScore W2998896835C3013748606 @default.
• W2998896835 hasConceptScore W2998896835C55493867 @default.
• W2998896835 hasConceptScore W2998896835C71924100 @default.
• W2998896835 hasConceptScore W2998896835C86803240 @default.
• W2998896835 hasConceptScore W2998896835C89423630 @default.
• W2998896835 hasFunder F4320311498 @default.

• next